AxioMx Assists DTRA in the Development of Anti-Ebola Virus Antibodies
Posted on Dec 10, 2014
The global effort to combat the spread of Ebola has been joined by AxioMx Inc., a Branford, Connecticut-based biotechnology company that has formed a partnership with the Defense Threat Reduction Agency (DTRA), a U.S. Department of Defense organization tasked with countering weapons of mass destruction, and the U.S. Army Edgewood Chemical Biological Center, the nation’s principle research and development resource for non-medical chemical biological defense.
Because of its expertise in rapid recombinant antibody development, AxioMx was recruited to assist DTRA in the search for antibodies against the Ebola virus. According to Dr. Michael Weiner, chief scientific officer and founder of AxioMx, “We are pleased to have this opportunity to collaborate with DTRA in the international fight against Ebola. To support the generation of diagnostic agents for this growing biothreat, AxioMx is utilizing its rapid antibody development platform, which we have successfully used to develop antibodies for other biothreat reduction programs.”
AxioMx is a well-established leader in the field of research antibody discovery. Rapid Liquid Screening, the innovative methodology pioneered by AxioMx, is particularly well suited to address the urgent need for weapons against Ebola. “Our ability to develop an antibody in less than half the time required by traditional methods provides a unique benefit in this situation,” explains Weiner. “AxioMx can provide timely support to those who need it the most urgently: U.S. troops stationed abroad and all members of the global community at risk of exposure to this exponentially spreading epidemic.”
About AxioMx Inc.
AxioMx, founded in 2012 and based in Branford, Connecticut, is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics, and proteomics organizations. AxioMx’s unique platform of proprietary phage display libraries, Rapid Liquid Screening, and affinity maturation methods enables the fast delivery of recombinant antibodies with high specificity, affinity, and reproducibility that are optimized to perform a desired application. The company offers a full range of custom antibody discovery and development services for the research, diagnostic, and therapeutic marketplaces. For more information about AxioMx, please visit www.axiomxinc.com.